Other languages Shanghai Junshi Biosciences Co., Ltd. OTC Markets

Equities

SHJBF

CNE100003FF7

Market Closed - OTC Markets Other stock markets 09:51:46 2024-03-20 am EDT			5-day change	1st Jan Change
1.86 ^USD	-9.71%		-.--%	-13.49%

Jun. 13	Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator	MT
Jun. 12	Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator	Jun. 13
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration	Jun. 12
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results	Jun. 12
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma	Jun. 11
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	Apr. 25
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	Apr. 24
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes	Apr. 24
Junshi Biosciences Gets Nod to Register Toripalimab Injection	Apr. 08
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	Apr. 07
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	Apr. 02
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	Apr. 02
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	Mar. 28
Junshi Bio's 2023 Loss Widens, Misses Estimates	Feb. 25
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23
Junshi Biosciences Proposes Share Buyback	Feb. 02
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA	Feb. 01
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority	Feb. 01
Shanghai Junshi Biosciences to Narrow Losses	Jan. 31
Junshi Bio Inks 40 Million Yuan Deal With Shanghai Allink Biotherapeutics	Jan. 31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shanghai Junshi Biosciences Co., Ltd. OTC Markets

Equities

SHJBF

CNE100003FF7

Other languages

Filters